Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
05 apr 2007 - 08:16
Statutaire naam
Crucell N.V.
Titel
Crucell broadens pandemic preparedness with grant awarded to develop H5N1 Influenza vaccine
Bericht
Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced it had received a European Commission-funded grant toward the development of a pandemic influenza vaccine. The €1.7 million grant, which was awarded to a consortium of nine leading universities and companies working in the field of influenza research, will finance pre-clinical and clinical testing of H5N1 vaccines.
Gerelateerde downloads
Datum laatste update: 01 september 2024